CSMD2

Across TCGA pan-cancer cohorts, CSMD2 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated CSMD2 data layer compared with 22 for mass-spec protein and 1 for mass-spec protein.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher CSMD2 Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated CSMD2 expression acts as an unfavorable survival marker, although some lineages such as UCEC and COAD show a favorable association.

UCEC, COAD, and THCA are the cancer types where CSMD2 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	DFS	Median	II,III,IV	0.892	0.414	.002	32	view →
COAD	DFS	Median	All	0.900	0.765	.007	21	view →
THCA	DFS	Median	All	0.325	0.846	<.001	12	view →
ACC	OS	Median	All	0.209	0.628	.015	9	view →
LUAD	OS	Median	IV	0.114	0.560	.038	6	view →
BLCA	DFS	Median	All	1.000	0.306	.039	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

CSMD2–UCEC (DFS)

Open the UCEC breakdown →